drugset / Trial / NCT02492438

13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

NCT02492438

Phase 4 Completed 154 enrolled AZ Sint-Jan AV Pfizer · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

Timeline

Start
2013-02
Primary completion
2014-02
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine
Subject Prevnar 13 Vaccine